CTIC - CTI BioPharma Corp.
1.84 0.00 (0.00%)
After hours: 5:02PM EDT
| Previous Close | 1.82 |
| Open | 1.83 |
| Bid | 1.75 x 2900 |
| Ask | 2.36 x 3100 |
| Day's Range | 1.83 - 1.87 |
| 52 Week Range | 1.75 - 5.36 |
| Volume | 223,722 |
| Avg. Volume | 711,582 |
| Market Cap | 106.685M |
| Beta | -0.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | Feb 28, 2018 - Mar 5, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.75 |
- ACCESSWIRE•19 days ago
CTI BioPharma Corp. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / CTI BioPharma Corp. (NASDAQ: CTIC ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern Time. ...
- Zacks•19 days ago
CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates
CTI BioPharma (CTIC) delivered earnings and revenue surprises of 13.04% and 104.33%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•20 days ago
CTI BioPharma: 2Q Earnings Snapshot
The Seattle-based company said it had a loss of 20 cents per share. The biotechnology company posted revenue of $613,000 in the period. The company's shares closed at $2.25. A year ago, they were trading ...
- PR Newswire•20 days ago
CTI BioPharma Reports Second Quarter 2018 Financial Results
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE , Aug. 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the second quarter ...
- PR Newswire•26 days ago
CTI BioPharma to Report Second Quarter 2018 Financial Results on August 2, 2018
SEATTLE , July 26, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its second quarter 2018 financial results on Thursday, August ...
- Zacks•last month
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
CTI BioPharma (CTIC) conducts Type B meeting with the FDA to discuss a regulatory pathway for its lead pipeline candidate Pacritinib, currently under study for the treatment of myelofibrosis.
- Benzinga•last month
Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 18) Abbott Laboratories (NYSE: ABT )(reported better-than-expected ...
- ACCESSWIRE•last month
Today’s Research Reports on Stocks to Watch: CTI BioPharma and Crinetics Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / July 19, 2018 / Shares of CTI Biopharma tanked nearly 44% yesterday while shares of Crinetics Pharmaceuticals exploded 44%. The former announced an update from an FDA meeting regarding the company's investigational drug pacritinib. Per FDA feedback, the company will now have to conduct a Phase 3 trial.
Market Realist•last monthCTI BioPharma Has Fallen Almost 39% Today
Why Is CTI BioPharma Stock Down Today? On July 18, CTI BioPharma (CTIC) announced the outcome of its type B meeting with the FDA related to its investigational drug pacritinib. As per the FDA’s feedback, the company now needs to conduct a Phase 3 trial to evaluate this second-generation JAK2 inhibitor for the treatment of myelofibrosis patients suffering from thrombocytopenia or who have already been treated with ruxolitinib.
- Motley Fool•last month
Why CTI BioPharma Corp. Crashed Today
The FDA's requirement of a new late-stage clinical study caused the biotech stock to plunge.
- PR Newswire•last month
CTI BioPharma Announces Pacritinib Program Update Following Type B Meeting with U.S. FDA
SEATTLE, July 18, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that it recently conducted a Type B meeting with the U.S. Food and Drug Administration (FDA) for its lead product candidate pacritinib. The purpose of the meeting was to discuss the regulatory pathway for pacritinib. Based on FDA feedback, the Company plans to conduct a randomized Phase 3 study in patients with myelofibrosis.
- Zacks•last month
Pharma Stock Roundup: PFE to Split Into 3 Units, J&J to Pay $4.7B in Talc Lawsuit
Pfizer (PFE) is re-organizing its business into three new units, effective 2019. A St Louis jury orders J&J (JNJ) to pay $4.69 billion in a lawsuit related to its talc-based products.
- Zacks•last month
CTI BioPharma Falls After Failure of Pivotal Lymphoma Study
CTI BioPharma (CTIC) and partner Servier announce that a pivotal study evaluating a Pixuvri combination regimen in non-Hodgkin lymphoma fails to improve progression free survival.
- Motley Fool•last month
Why CTI BioPharma, PetMed Express, and Pfizer Slumped Today
Read on to see which of these companies drew the ire of Donald Trump.
- Associated Press•last month
Groupon, JPMorgan Chase rise, Twitter, CTI BioPharma fall
Stocks that moved substantially or traded heavily Monday: Groupon Inc., up 47 cents to $4.83 Recode reported that the online coupon company is looking for a buyer. Twitter Inc., down $2.51 to $44.14 The ...
- Motley Fool•last month
Why CTI BioPharma Corp. Is Sinking Today
Shares tumble in response to disappointing clinical news. Here's what investors need to know.
- MarketWatch•last month
UPDATE: CTI BioPharma stock slides 12% after failed trial of treatment for non-Hodgkin lymphoma
CTI BioPharma Corp.'s shares (ctic) fell 12% in premarket trade Monday, after the biotech said a late-stage trial of a treatment for the blood cancer non-Hodgkin lymphoma failed to meet its main goals. The Phase III trial evaluating Pixuvri combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of an improvement in progression-free survival, the company said in a statement.
- Reuters•last month
CTI Biopharma's cancer drug fails late-stage trial
CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. The drug, Pixuvri, did not show a statistically significant improvement in the length of time patients survived without any progression in the disease. CTI's treatment was being tested in combination with Roche Holding's Rituxan in patients with aggressive B-cell Non-Hodgkin lymphoma.
- Reuters•last month
CTI Biopharma's cancer treatment fails to meet trial goal
CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial. The drug, Pixuvri, was being tested in patients with aggressive B-cell Non-Hodgkin ...
- PR Newswire•last month
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI® (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
PIXUVRI® plus rituximab did not show a statistically significant improvement in progression-free survival compared to gemcitabine plus rituximab SEATTLE , July 9, 2018 /PRNewswire/ -- CTI BioPharma Corp. ...
- PR Newswire•2 months ago
CTI BioPharma Announces the Continuation without Modification of PAC203 Phase 2 Study of Pacritinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib
SEATTLE, July 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee (IDMC) of PAC203, the study will continue without modification and that a second interim review will be conducted in the third quarter of 2018. The IDMC did not identify any drug- or dose-related safety concerns and specifically did not identify any concerns about cardiac or bleeding events. The PAC203 study is evaluating the safety and efficacy of three dosing schedules (100 mg once daily, 100 mg twice daily and 200 mg twice daily) over 24 weeks in patients with myelofibrosis previously treated with ruxolitinib.
- Benzinga•2 months ago
The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus
Biotech stocks came under pressure earlier in the week, weighed down by negative trial results, mixed FDA verdicts and overall pessimistic broader market sentiment, but recovered in the last two sessions. ...
- PR Newswire•2 months ago
CTI BioPharma to Present at the JMP Securities 2018 Life Sciences Conference
SEATTLE , June 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York, ...
- Simply Wall St.•2 months ago
Analysts Expect Breakeven For CTI BioPharma Corp (NASDAQ:CTIC)
CTI BioPharma Corp’s (NASDAQ:CTIC): CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.Read More...
- PR Newswire•3 months ago
CTI BioPharma to Present at the Jefferies 2018 Global Healthcare Conference
SEATTLE , June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY ...
